$15.82
0.976.53%
Last update: Nov 6, 4:00 PM

The average analyst price target for Aktis Oncology is $31.50, 99.1% above the current price. Of 9 analysts, 8 rate it Buy and 1 Hold. Targets range from $1 to $40. The latest change came on Sep 9, 2026, when Oppenheimer initiated coverage of Aktis Oncology with an Outperform rating and a $40 price target.
Price Target Range — 5 Quarters
Analyst Consensus — 9 Analysts
Rating Trend — Last 9 Months